Innovation and IP in Medtech Stocks - How Patents Build Leaders
Aethlon Medical (NASDAQ: AEMD) has strengthened its intellectual property portfolio with two significant patent approvals for its Hemopurifier® device. The US Patent No. 12,409,260 for Long COVID treatment will issue on September 9, 2025, expiring in 2042, while the Unitary European Patent 4136453 for COVID-19-associated coagulopathy was issued July 9, 2025, expiring in 2041.
The Hemopurifier®, which holds FDA Breakthrough Device Designation, is designed to remove viruses, viral fragments, and tumor-derived extracellular vesicles from circulation. The company's IP portfolio includes 14 international patents for exosome removal and 4 US patents for microvesicular particle removal, with protection extending through 2031 in various European countries.
This development comes as the global medical device market, currently valued at $680 billion, is projected to exceed $1 trillion within 10 years at a 6% CAGR, highlighting the critical importance of IP in the medtech sector.
Aethlon Medical (NASDAQ: AEMD) ha rafforzato il proprio portafoglio di proprietà intellettuale con due approvazioni brevettuali rilevanti per il dispositivo Hemopurifier®. Il brevetto USA n. 12.409.260 per il trattamento del Long COVID sarà rilasciato il 9 settembre 2025 e scadrà nel 2042, mentre il Brevetto Europeo Unitario 4136453 per la coagulopatia associata al COVID-19 è stato concesso il 9 luglio 2025 e scadrà nel 2041.
L'Hemopurifier®, che ha ottenuto la designazione FDA Breakthrough Device, è progettato per rimuovere virus, frammenti virali e vescicole extracellulari derivate da tumori dalla circolazione. Il portafoglio IP dell'azienda comprende 14 brevetti internazionali per la rimozione di esosomi e 4 brevetti USA per la rimozione di microvescicole, con protezione estesa fino al 2031 in vari Paesi europei.
Questo sviluppo arriva mentre il mercato globale dei dispositivi medici, attualmente valutato 680 miliardi di dollari, è previsto superare 1.000 miliardi di dollari entro 10 anni con un CAGR del 6%, sottolineando l'importanza strategica della proprietà intellettuale nel settore medtech.
Aethlon Medical (NASDAQ: AEMD) ha reforzado su cartera de propiedad intelectual con dos aprobaciones de patentes importantes para su dispositivo Hemopurifier®. La patente estadounidense n.º 12.409.260 para el tratamiento del Long COVID se expedirá el 9 de septiembre de 2025 y vence en 2042, mientras que la Patente Unitaria Europea 4136453 para la coagulopatía asociada a la COVID-19 se emitió el 9 de julio de 2025 y caduca en 2041.
El Hemopurifier®, que cuenta con la designación FDA Breakthrough Device, está diseñado para eliminar virus, fragmentos virales y vesículas extracelulares derivadas de tumores de la circulación. La cartera de PI de la compañía incluye 14 patentes internacionales para la eliminación de exosomas y 4 patentes estadounidenses para la eliminación de partículas microvesiculares, con protección extendida hasta 2031 en varios países europeos.
Este avance se produce cuando el mercado mundial de dispositivos médicos, valorado actualmente en 680.000 millones de dólares, se proyecta que supere 1 billón de dólares en 10 años con un CAGR del 6%, lo que destaca la importancia crítica de la propiedad intelectual en el sector medtech.
Aethlon Medical (NASDAQ: AEMD)은 자사 Hemopurifier® 장치와 관련해 두 건의 주요 특허 승인으로 지식재산 포트폴리오를 강화했습니다. 미국 특허 제12,409,260호(롱코비드 치료)는 2025년 9월 9일 등록될 예정이며 만료일은 2042년이고, 유니터리 유럽 특허 4136453호(코로나19 연관 응고장애)는 2025년 7월 9일에 발급되어 2041년에 만료됩니다.
FDA 혁신기기(Breakthrough Device) 지정을 받은 Hemopurifier®는 혈류에서 바이러스, 바이러스 파편 및 종양 유래 세포외 소포를 제거하도록 설계되었습니다. 회사의 IP 포트폴리오에는 엑소좀 제거 관련 국제 특허 14건과 미국 내 마이크로베시클 제거 특허 4건이 포함되어 있으며, 여러 유럽 국가에서는 2031년까지 보호가 확장되어 있습니다.
이 같은 발전은 현재 6,800억 달러 규모인 전 세계 의료기기 시장이 연평균 성장률(CAGR) 6%로 향후 10년 내 1조 달러를 초과할 것으로 전망되는 가운데 이루어졌으며, 이는 메드테크 분야에서 지식재산의 중요성을 부각합니다.
Aethlon Medical (NASDAQ: AEMD) a renforcé son portefeuille de propriété intellectuelle avec deux approbations de brevets importantes pour son dispositif Hemopurifier®. Le brevet américain n° 12,409,260 pour le traitement du Long COVID sera délivré le 9 septembre 2025 et expirera en 2042, tandis que le brevet unitaire européen 4136453 pour la coagulopathie associée au COVID-19 a été délivré le 9 juillet 2025 et expirera en 2041.
L'Hemopurifier®, qui bénéficie de la désignation FDA Breakthrough Device, est conçu pour éliminer les virus, les fragments viraux et les vésicules extracellulaires dérivées de tumeurs de la circulation sanguine. Le portefeuille PI de la société comprend 14 brevets internationaux pour l'élimination des exosomes et 4 brevets américains pour l'élimination des particules microvésiculaires, avec une protection étendue jusqu'en 2031 dans plusieurs pays européens.
Cette évolution intervient alors que le marché mondial des dispositifs médicaux, actuellement évalué à 680 milliards de dollars, devrait dépasser 1 000 milliards de dollars d'ici 10 ans avec un TCAC de 6%, soulignant l'importance stratégique de la propriété intellectuelle dans le secteur medtech.
Aethlon Medical (NASDAQ: AEMD) hat sein geistiges Eigentum mit zwei wichtigen Patenterteilungen für das Hemopurifier®-Gerät gestärkt. Das US-Patent Nr. 12.409.260 für die Behandlung von Long COVID wird am 9. September 2025 erteilt und läuft 2042 aus, während das Einheitspatent 4136453 für COVID-19-assoziierte Koagulopathie am 9. Juli 2025 erteilt wurde und 2041 ausläuft.
Der Hemopurifier®, der die FDA Breakthrough Device Designation besitzt, ist darauf ausgelegt, Viren, Virusfragmente und tumorabgeleitete extrazelluläre Vesikel aus dem Blutkreislauf zu entfernen. Das IP-Portfolio des Unternehmens umfasst 14 internationale Patente zur Exosomen-Entfernung und 4 US-Patente zur Entfernung mikrovesikulärer Partikel, mit Schutzverlängerungen bis 2031 in verschiedenen europäischen Ländern.
Diese Entwicklung erfolgt vor dem Hintergrund, dass der globale Medizingerätemarkt, derzeit mit 680 Milliarden Dollar bewertet, bei einem CAGR von 6% innerhalb von 10 Jahren die 1 Billion Dollar-Marke übersteigen dürfte, was die zentrale Bedeutung von IP im MedTech-Sektor unterstreicht.
- None.
- Hemopurifier® device remains in research and development stage for Long COVID applications
- No current commercialization timeline provided
- Faces competition in rapidly growing medical device market
Insights
Aethlon Medical strengthens competitive position with new patents for Hemopurifier® device targeting Long COVID and coagulation complications through 2042.
Aethlon Medical has secured two strategic patents that significantly expand its IP portfolio for the Hemopurifier® device. The US patent (No. 12,409,260) for Long COVID treatment and European patent (No. 4136453) for COVID-19-associated coagulopathy represent important additions to their existing 22+ patents across international markets.
What makes these patents particularly valuable is their extended protection timeline – the US patent includes an additional 385 days of term adjustment, extending protection until 2042, while the European patent provides coverage through 2041. This long-term exclusivity window creates a substantial competitive moat in a global medtech market projected to reach
The Hemopurifier® technology occupies a distinctive niche with its extracorporeal approach to removing viral particles and tumor-derived extracellular vesicles from circulation. Having secured FDA Breakthrough Device Designation for both advanced cancer and life-threatening viral infections positions Aethlon in two potentially lucrative treatment areas with significant unmet needs.
While still in R&D phase specifically for Long COVID applications, these patents strategically position Aethlon to capitalize on post-pandemic healthcare challenges. The expansion of their IP portfolio in areas with limited treatment options demonstrates smart positioning in a medtech landscape where, as industry reports note, patents are "critical for securing funding, negotiating partnerships, and positioning as industry leaders." The Hemopurifier®'s unique mechanism targeting mannose-rich surfaces on viral proteins and EVs creates a differentiated technology profile that's now protected across multiple potential applications and geographies.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 4, 2025) - Investorideas.com, a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking at innovation and the importance of IP in medtech,, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.
Innovation and IP in Medtech Stocks - How Patents Build Leaders
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6292/264981_c84248ed9421986d_001full.jpg
Medical Device Online reported in July, "The global medical device market is estimated to be currently about
Aethlon Medical, Inc. (NASDAQ: AEMD) with its unique medical device, Hemopurifier®, is building an impressive list of patents issued and pending. It just announced that US Patent No. 12,409,260 ("the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent)" directed to the treatment of COVID-19-associated coagulopathy ("CAC") was issued July 9, 2025.
From the news:
The 260 Patent is intended to protect the use of the Hemopurifier® in the United States to treat patients that have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post infection. The 260 Patent additionally protects the treatment of patients experiencing Long COVID symptoms by the removal of circulating COVID-19 spike protein.
The 453 Patent is intended to protect the use of the Hemopurifier® for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC.
The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.
"We believe securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need," said James Frakes, CEO and CFO of Aethlon. "While the Hemopurifier® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."
The Aethlon Hemopurifier® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extra-corporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses, fragments of viruses, and extracellular vesicles has been demonstrated in both in vitro studies and in human patients.
The Hemopurifier® holds a US Food and Drug Breakthrough Device Designation for:
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
In addition to this patent news, Aethlon has the following patents issued and multiple patents pending in the US and Internationally:
International Patents issued
14 patents covering exosomes and microvesicular particle removal
• Patent protection extending to 2031 in Germany, France, Great Britain and Spain
• Patent protection extending to 2027 in Canada, Switzerland, Italy, Netherlands, Sweden, Hong Kong, Demark and Ireland
• 4 patents covering removal of COVID-19 viral particles and associated exosomes.
• Patent protection extending to 2041 in Unitary Patent member states, Switzerland, Great Britain and Spain
Issued Patents In United States:
• 4 patents issued covering extracorporeal removal of microvesicular particles, patent protection until 2029
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), a pioneer in innovative life-support and diagnostic technologies recently announced it received US Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company's strategy to penetrate the
From the news:
The patent provides further protection for the underlying core technology of Inspira's ART500 system, which is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. This capability targets a large, underserved patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems, significantly expanding the potential market for Inspira's technology. This approval strengthens Inspira's intellectual property portfolio and reinforces the Company's technological leadership in the field of advanced extracorporeal life support.
Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of
The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500's functionality, design, and clinical applications. Inspira is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage.
In late August, Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company dedicated to advancing precision nerve-targeted treatments announced that European Patent Office (EPO) has granted Patent No. 3,697,298 (the '298 patent), titled, "Medical Device with Circuitry for Capturing and Processing Physiological Signals." The newly issued '298 patent relates to use of its proprietary technology to collect and process sensing data for real-time physiological monitoring with broad application use that includes coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.
Earlier this year, Royal Philips (NYSE: PHG) announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech patent applications. This achievement underscores the company's ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per patient.
From the news:
AI-enabled cardiovascular ultrasound platform
The innovations by Philips, which can boast 134 years of innovation history with its research and development programs around the globe, improved the health and well-being of nearly 2 billion people in 2024, keeping it on track towards its target of 2.5 billion lives improved in 2030.
Roy Jakobs, CEO of Royal Philips said: "For more than 130 years, Philips has been at the forefront of innovations improving people's lives. The 2024 European patent rankings show how we continue to innovate in the hospital and the home - helping to deliver better care for more people. To continue driving greater impact, we have shifted our innovation closer to customers. We want to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being."
As informatics and AI increasingly create value for healthcare, both at the hospital as well as at home, approximately half of the company's R&D investments are focused on these technologies.
Some of the informatics and AI-powered innovations that Philips launched in 2024 include:
- The new Azurion image-guided therapy system with advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients.
- FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging and increase automation and productivity, reinforcing Philips' #1 global position in cardiovascular ultrasound.
- The new Philips Spectral CT 7500 RT, enabling personalized radiation therapy planning to deliver better care to more cancer patients.
- FDA approval for the LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.
In total, Philips contributed 1,231 European patent applications across various domains, the most of any Dutch company and continuing the company's legacy as one of the top applicants since the EPO started publishing the rankings in 2004.
Based on market projections from leading analysts, the medical device market is set for significant expansion, fueled by technological advancements and growing healthcare needs.
Aethlon Medical, Inc. (NASDAQ: AEMD) is advancing its Hemopurifier® blood purification device globally with a growing patent portfolio to strengthen its long-term competitive advantage in the sector.
Research biotech and medical device/ tech stocks at Investorideas.com
https://www.investorideas.com/BIS/
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.
Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com. AEMD is an annual featured showcase stock at Investorideas.com This is not investment opinion. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264981
FAQ
What new patents did Aethlon Medical (NASDAQ: AEMD) receive for its Hemopurifier device in 2025?
What is the Aethlon Hemopurifier device designed to do?
How long does Aethlon Medical's patent protection extend?
What FDA designations does the Aethlon Hemopurifier currently hold?
How large is the global medical device market expected to grow?
